Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Effect of Pyronaridine on the Pharmacokinetics of MK-7602 in Healthy Participants

NCT07919028 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07919028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Effect of Pyronaridine on the Pharmacokinetics of MK-7602 in Healthy Participants
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 4, 2027
Completion date
April 5, 2027
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy

Arms

As registered; 2 arms.

  • Period 1: MK-7602 ExperimentalMK-7602

    Participants will receive an oral dose of MK-7602 once daily on Days 1, 2, and 3 of Period 1.

  • Period 2: MK-7602 + Pyronaridine ExperimentalMK-7602, Pyronaridine

    Participants will receive oral doses of MK-7602 and pyronaridine once daily on Days 1, 2, and 3 of Period 2.

Primary endpoints

Registered primary outcome measures; 4 primary.

  • Area Under the Curve From Time 0 to the Next Dosing Interval (AUC0-tau) of MK-7602 At designated timepoints (up to approximately 21 days)

    Blood samples will be collected to determine the AUC0-tau of MK-7602 with and without pyronaridine.

  • Maximum Plasma Concentration (Cmax) of MK-7602 At designated timepoints (up to approximately 21 days)

    Blood samples will be collected to determine the Cmax of MK-7602 with and without pyronaridine.

  • Number of Participants Who Experience an Adverse Event (AE) Up to approximately 2 months

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. The number of participants who experience an AE will be reported.

  • Number of Participants Who Discontinue Study Intervention Due to an AE Up to approximately 20 days

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Lead sponsor's other trials

Merck Sharp & Dohme LLC, most recent start first.